02.12.2015 Lviv Regional Cardiocenter received 51 packages of “Revatsio”, active ingredient is “Sildenafil”. Neither we nor patients weren’t reported on this. We found out about it by accident.

According to the chief doctor S.Pavlik 14 patients, included in the “Regional Program of medical care improving for patients with pulmonary hypertension in Lviv region” will be able to receive “Revatsio” from 04.12.2015, in an amount that corresponds to a predetermined by Lviv Regional Cardiocenter doses.

In addition, the chief doctor said that medicines will be given to patients according to the procedure established by the Order on this occasion. However, our request to provide a copy of this Order was rejected.

We remind that during the development of the Regional Program all 14 patients were hospitalized in cardiocenter and got appropriate examinations, based on which each was identified with individual dose of “Revatsio” (“Sildenafil”) and “Ventavis” (“iloprost” ), as evidenced by extracts from patient medical histories.

That is, the number of  “Revatsio” in 51 pack. was ordered in accordance with pre-defined individual doses for each of the 14 patients.

1.2 million UAH were allocated by Lviv Regional Council for the implementation of the Regional Program specifically for 3 months and also in accordance with pre-defined individual doses for each of the 14 patients.

04/12/2015 we came to Cardiocenter to get medicines. However, we were informed that each of the 14 patients will not receive “Revatsio” in predefined by Cardiocenter individual doses, but they will get the minimum dose, which will be increased in case of deterioration of patient’s health.

By this Cardiocenter questioned previous 14 extracts from patient medical history made by them self, which specified individual doses for each patient with pulmonary hypertension in Lviv region.

Please note that the objectives of the Regional Program are:

– Ensuring purchase of the required number of sildenafil and iloprost for the treatment of patients with pulmonary arterial hypertension;

– Assign specific treatment of pulmonary arterial hypertension patients, according to the register;

– Improving the quality and length of life of patients with pulmonary arterial hypertension (survival during the year).

That is, the program does not provide regional research actions of medicines on the patient’s body. Any experiments in this direction, pose a threat to life and health of the patient, as by taking a minimal, and not individually defined dose the person doesn’t feel improvement of the life’s quality.

IT IS EQUAL AS TO THROW THIS MEDICATION IN THE TRASH, NAMELY IT LEAVES NO THERAPEUTIC EFFECT.

WHEN THE NECESSARY FOR 3 MONTH TREATMENT MEDICATIONS ARE AVAILABLE, IT IS A CRIMINAL TO LIMIT PEOPLE IN THE REQUIRED DOSES. THEY HOLD CONSULTATIONS WITHOUT A REASON, HAVING NO QUALIFICATION TO QUESTION THE THERAPEUTIC EFFECT OF 50 MG OF GENERIC “SILDENAFIL” OF UKRAINIAN MANUFACTURER AND 20 MG OF ORIGINAL “SILDENAFIL” (“REVATSIO”), ARGUING THAT THE EFFECT OF ORIGINAL PRODUCTS IS STRONGER, WHILE NOT REFERRING TO ANY ACADEMIC RESEARCH. ALL THIS IS UNFOUNDED.

We hope that the Lviv Regional Cardiocenter will not question 14 extracts from medical histories of patients with pulmonary hypertension in Lviv region and all 14 patients will be given medicines “Revatsio”, “Ventavis” in the amount which corresponds to their individually defined doses.

P.S. We add photos of appeal letter with individually defined doses of 8 patients included in the regional program and photos of request to Cardiocenter to provide a copy of the chief doctor’s Order, which determines the procedure for giving medicines of “Revatsio” and “Ventavis.”